newsfilter
← Earnings
Earnings Releases·

Aprea Therapeutics — Third Quarter 2026 Earnings Summary

Aprea Therapeutics reported a net loss of $4.8 million for the third quarter ended September 30, 2026, with research and development expenses rising to $3.3 million primarily due to increased costs for the ACESOT-1051 trial. The company holds $37.8 million in cash and cash equivalents as of September 30, 2026, providing a runway into the first quarter of 2028. Clinical progress includes expanding the ACESOT-1051 Phase 1 trial to nine sites and planning to present updated interim data at the EORTC-NCI-AACR Symposium in November 2026. Additionally, Aprea has determined the recommended Phase 2 dose for its ATR inhibitor ATRN-119 and is exploring combination therapies for this candidate.

Company
APREA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology